Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice

Arch Toxicol. 1998 Sep;72(9):574-9. doi: 10.1007/s002040050545.

Abstract

The relationship between the rhythm in tissue nonprotein sulphydryl groups (NPSH) and that in 1,2-diamine (trans-I)-cyclohexane oxalatoplatinum (1-OHP) toxicity was investigated in a total of 266 male B6D2F1 mice, using buthionine sulphoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase. Mice were synchronized with an alternation of 12 h light (L) and 12 h darkness (D; LD 12:12), and circadian time was expressed in hours after light onset (HALO). NPSH was measured in liver, jejunum and bone marrow at 0, 8 and 16 HALO. Dosing 1-OHP at these times achieved intermediate. high or low toxicity respectively. The physiological circadian rhythm in NPSH content was statistically significant in all tissues studied, with a maximum at the transition from D to L (0 HALO). BSO administration (450 mg/kg i.p., 4 h before sampling) induced a large depletion in liver and jejunum NPSH at their physiological peak (0 HALO), but exerted no significant effect at their trough (8 HALO). As a result, 24 h rhythm was suppressed in liver and jejunum, but remained similar to the physiological one in bone marrow. BSO enhanced 1-OHP-induced mortality and jejunal toxicity, but exerted no significant effect upon bone marrow toxicity. Despite these differences, 1-OHP remained least toxic at 16 HALO, near the middle of the dark span, which corresponds to maximum activity in the circadian rest/activity cycle. Our results show that mean NPSH levels in liver seem to account for the mean level of 1-OHP toxicity, while jejunal NPSH rhythm plays an important role in the intestinal toxicity rhythm of this drug.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Bone Marrow / drug effects
  • Buthionine Sulfoximine / pharmacology*
  • Circadian Rhythm*
  • Femur / drug effects
  • Intestine, Small / drug effects*
  • Jejunum / drug effects
  • Liver / chemistry
  • Liver / drug effects*
  • Male
  • Mice
  • Organoplatinum Compounds* / administration & dosage
  • Organoplatinum Compounds* / pharmacokinetics
  • Organoplatinum Compounds* / toxicity
  • Oxaliplatin
  • Proteins / metabolism
  • Random Allocation
  • Sulfhydryl Compounds / metabolism*
  • Time Factors

Substances

  • Organoplatinum Compounds
  • Proteins
  • Sulfhydryl Compounds
  • Oxaliplatin
  • Buthionine Sulfoximine